SLN
Income statement / Annual
Last year (2024), Silence Therapeutics plc's total revenue was $43.26 M,
an increase of 70.47% from the previous year.
In 2024, Silence Therapeutics plc's net income was -$45.31 M.
See Silence Therapeutics plc,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
| Period Ended |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
| Operating Revenue |
$43.26 M |
$25.38 M |
$17.50 M |
$12.42 M |
$5.48 M |
$244,000.00 |
$0.00 |
$16,000.00 |
$770,000.00 |
$0.00 |
| Cost of Revenue |
$11.81 M
|
$10.32 M
|
$10.88 M
|
$7.46 M
|
$3.76 M
|
$0.00
|
$9.74 M
|
$7.94 M
|
$8.71 M
|
$7.11 M
|
| Gross Profit |
$31.45 M
|
$15.06 M
|
$6.62 M
|
$4.96 M
|
$1.72 M
|
$244,000.00
|
-$9.74 M
|
-$7.93 M
|
-$7.94 M
|
-$7.11 M
|
| Gross Profit Ratio |
0.73
|
0.59
|
0.38
|
0.4
|
0.31
|
1
|
0
|
-495.44
|
-10.31
|
0
|
| Research and Development Expenses |
$67.88 M
|
$44.03 M
|
$35.61 M
|
$30.77 M
|
$20.21 M
|
$13.34 M
|
$9.74 M
|
$7.94 M
|
$8.71 M
|
$7.11 M
|
| General & Administrative Expenses |
$26.88 M
|
$20.64 M
|
$19.61 M
|
$20.01 M
|
$13.98 M
|
$9.64 M
|
$10.83 M
|
$6.46 M
|
$3.97 M
|
$2.66 M
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$26.88 M
|
$20.64 M
|
$19.61 M
|
$20.01 M
|
$13.98 M
|
$9.64 M
|
$10.83 M
|
$6.46 M
|
$3.97 M
|
$2.66 M
|
| Other Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$3.37 M
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Operating Expenses |
$94.77 M
|
$64.66 M
|
$55.21 M
|
$50.77 M
|
$37.56 M
|
$22.98 M
|
$20.57 M
|
$14.41 M
|
$12.68 M
|
$9.77 M
|
| Cost And Expenses |
$106.58 M
|
$74.98 M
|
$66.09 M
|
$58.23 M
|
$41.33 M
|
$22.98 M
|
$20.57 M
|
$14.41 M
|
$12.68 M
|
$9.77 M
|
| Interest Income |
$0.00
|
$1.45 M
|
$226,000.00
|
$10,000.00
|
$129,000.00
|
$27,000.00
|
$39,000.00
|
$206,000.00
|
$1.54 M
|
$175,000.00
|
| Interest Expense |
$0.00
|
$34,000.00
|
$47,000.00
|
$8,000.00
|
$323,000.00
|
$163,000.00
|
$0.00
|
$15,000.00
|
$0.00
|
$0.00
|
| Depreciation & Amortization |
$0.00
|
$498,000.00
|
$482,000.00
|
$427,000.00
|
$496,000.00
|
$482,000.00
|
$399,000.00
|
$433,000.00
|
$310,000.00
|
$182,000.00
|
| EBITDA |
-$63.32 M |
-$49.78 M |
-$47.89 M |
-$45.42 M |
-$35.53 M |
-$22.36 M |
-$20.17 M |
-$3.33 M |
-$11.60 M |
-$9.59 M |
| EBITDA Ratio |
-1.46
|
-1.96
|
-2.74
|
-3.66
|
-6.43
|
-91.09
|
0
|
-2089.63
|
-15.06
|
0
|
| Operating Income Ratio |
-1.46
|
-1.95
|
-2.78
|
-3.69
|
-6.54
|
-93.17
|
0
|
-899.44
|
-15.46
|
0
|
| Total Other Income/Expenses Net |
$18.86 M
|
-$706,000.00
|
$1.23 M
|
-$42,000.00
|
-$194,000.00
|
-$136,000.00
|
$45,000.00
|
$10.62 M
|
$1.54 M
|
$340,000.00
|
| Income Before Tax |
-$44.46 M
|
-$50.31 M
|
-$47.37 M
|
-$45.86 M
|
-$36.04 M
|
-$22.87 M
|
-$20.53 M
|
-$3.78 M
|
-$10.36 M
|
-$9.43 M
|
| Income Before Tax Ratio |
-1.03
|
-1.98
|
-2.71
|
-3.69
|
-6.58
|
-93.73
|
0
|
-235.94
|
-13.46
|
0
|
| Income Tax Expense |
-$845,000.00
|
-$7.04 M
|
-$6.88 M
|
-$6.45 M
|
-$3.49 M
|
-$3.29 M
|
-$2.12 M
|
-$2.16 M
|
-$1.92 M
|
-$2.78 M
|
| Net Income |
-$45.31 M
|
-$43.27 M
|
-$40.49 M
|
-$39.41 M
|
-$32.55 M
|
-$19.58 M
|
-$18.41 M
|
-$1.62 M
|
-$8.44 M
|
-$6.65 M
|
| Net Income Ratio |
-1.05
|
-1.71
|
-2.31
|
-3.17
|
-5.94
|
-80.25
|
0
|
-101.13
|
-10.96
|
0
|
| EPS |
-0.0003 |
-0.39 |
-0.42 |
-0.44 |
-0.4 |
-0.26 |
-0.26 |
-0.0231 |
-0.12 |
-0.1 |
| EPS Diluted |
-0.0003 |
-0.39 |
-0.42 |
-0.44 |
-0.4 |
-0.26 |
-0.26 |
-0.0231 |
-0.12 |
-0.1 |
| Weighted Average Shares Out |
$138.75 B
|
$111.28 M
|
$96.58 M
|
$88.95 M
|
$81.77 M
|
$75.13 M
|
$70.31 M
|
$69.94 M
|
$69.80 M
|
$64.02 M
|
| Weighted Average Shares Out Diluted |
$138.75 B
|
$111.28 M
|
$96.58 M
|
$88.95 M
|
$81.78 M
|
$75.13 M
|
$70.31 M
|
$69.94 M
|
$69.80 M
|
$64.02 M
|
| Link |
|
|
|
|
|
|
|
|
|
|
